Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 3;12(9):2501.
doi: 10.3390/cancers12092501.

Distinct Clinical Characteristics in Young-Onset Pancreatic Neuroendocrine Tumor

Suleyman Yasin Goksu  1   2 , Muhammet Ozer  1   3 , Syed Mohammad Ali Kazmi  1   2 , Nina Niu Sanford  4 , Todd A Aguilera  4 , Chul Ahn  5 , David Hsiehchen  1   2 , Aravind Sanjeevaiah  1   2 , Leticia Khosama  1 , Jonathan Bleeker  6 , Muslim Atiq  7 , Muhammad Shaalan Beg  1   2
Affiliations

Distinct Clinical Characteristics in Young-Onset Pancreatic Neuroendocrine Tumor

Suleyman Yasin Goksu et al. Cancers (Basel). .

Abstract

Background: We aimed to study the effect of socioeconomic differences and molecular characteristics on survival in patients with young-onset pancreatic neuroendocrine tumors (YOPNET) and typical-onset PNET (TOPNET).

Methods: We identified the patients with YOPNET (<50 years) and TOPNET (≥50 years) who underwent definitive surgery diagnosed between 2004 and 2016 using the National Cancer Database. We evaluated overall survival (OS) using the Kaplan-Meier and Cox regression methods before and after propensity score matching. A publicly available genomic dataset was used to compare mutation frequencies among the two groups.

Results: A total of 6259 patients with PNET were included, of which 27% were YOPNET. Patients with YOPNET were more likely to be Black, Hispanic, female, and have private insurance versus patients with TOPNET (all p < 0.001). Patients with YOPNET had a lower comorbidity score, but higher stage and tumor size (all p < 0.001). YOPNET was associated with a greater improved OS than TOPNET before and after propensity score matching (p < 0.001). On multivariable analysis, this survival difference persisted for YOPNET as an independent prognostic factor (unmatched p = 0.008; matched p = 0.01). For genomic analysis, patients with YOPNET had a lower rate of multiple endocrine neoplasia type-1 (MEN-1) mutation than patients with TOPNET (26% vs. 56%, p < 0.001).

Conclusions: YOPNET represents a disease with distinct clinical features. Patients with YOPNET who underwent definitive surgery had better OS than patients with TOPNET despite having higher stage and tumor size. YOPNET also had lower rate of MEN-1 mutation.

Keywords: age of onset; database; multiple endocrine neoplasia; mutation; neuroendocrine tumors; pancreas; propensity score; young adult.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
(A) Overall survival for unmatched groups, (B) the trends of survival in pancreatic neuroendocrine tumors with increasing age (YOPNET: Young-onset pancreatic neuroendocrine tumors, TOPNET: Typical-onset pancreatic neuroendocrine tumors).
Figure 2
Figure 2
A diagram for inclusion and exclusion criteria. (YOPNET: young-onset PNET, TOPNET: typical-onset PNET).
See this image and copyright information in PMC

References

    1. Halfdanarson T.R., Rabe K.G., Rubin J., Petersen G.M. Pancreatic neuroendocrine tumors (PNETs): Incidence, prognosis and recent trend toward improved survival. Ann. Oncol. 2008;19:1727–1733. doi: 10.1093/annonc/mdn351. - DOI - PMC - PubMed
    1. Dasari A., Shen C., Halperin D., Zhao B., Zhou S., Xu Y., Shih T., Yao J.C. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–1342. doi: 10.1001/jamaoncol.2017.0589. - DOI - PMC - PubMed
    1. Beeghly-Fadiel A., Luu H.N., Du L., Shi C., McGavic D.P., Parikh A.A., Raskin L. Early onset pancreatic malignancies: Clinical characteristics and survival associations. Int. J. Cancer. 2016;139:2169–2177. doi: 10.1002/ijc.30273. - DOI - PubMed
    1. Muniraj T., Jamidar P.A., Aslanian H.R. Pancreatic cancer: A comprehensive review and update. Dis. Mon. 2013;59:368–402. doi: 10.1016/j.disamonth.2013.08.001. - DOI - PubMed
    1. Raimondi S., Maisonneuve P., Lowenfels A.B. Epidemiology of pancreatic cancer: An overview. Nat. Rev. Gastroenterol. Hepatol. 2009;6:699–708. doi: 10.1038/nrgastro.2009.177. - DOI - PubMed

LinkOut - more resources